The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

DSM-Firmenich’s chair of the board of directors, Thomas Leysen (pictured above), has decided to retire from his role once his successor has been elected by the company’s shareholders.

The company said its ‘strategic direction’ is ‘fully set,’ prompting Leysen’s decision to step down and devote more time to his other corporate and non-profit mandates.

The board has unanimously proposed Richard Ridinger, currently an independent director of DSM-Firmenich, as his successor. Shareholders will be asked to approve his appointment at an Extraordinary General Shareholders Meeting to be held on 19 October 2026.

Ridinger brings extensive executive and board-level experience in global businesses across pharmaceuticals, home and personal care, and nutrition and health.

DSM-Firmenich praised his deep understanding of the company, positioning him well to succeed Leysen. The company said he will provide continuity to execute its strategy and create long-term value for shareholders and other stakeholders.

Since the formation of DSM-Firmenich, a result of the merger between Royal DSM and Firmenich in 2023, Leysen has provided guidance through a period of significant change and challenging market conditions.

The board thanked him for his leadership, adding that he has been ‘instrumental’ in positioning the company for its next growth phase.

Leysen commented: “With DSM-Firmenich now fully operating as one company, the portfolio tuning nearing completion with the closing of the Animal Nutrition & Health sale foreseen later this year, the executive committee rejuvenated and the margin improvement program well underway, it is an opportune moment to hand over to a new chair”.

“Richard has all the requisite experience to help bring DSM-firmenich to the next level. It has been a pleasure and an honour to chair the board during the formative stages of this unique company.”